Impact of Approved Drug Labeling on Chronic Opioid Therapy

Impact of Approved Drug Labeling on Chronic Opioid Therapy The public hearing will be held on February 7 and 8, 2013, from 9 a.m. to 4 p.m. (Day 1 of 2) The Food and Drug Administration (FDA) is announcing a public hearing to obtain information, particularly scientific evidence, such as study data or peer-reviewed analyses, on issues pertaining to the use of opioid drugs in the treatment of chronic pain.